Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Wedbush boosted their FY2024 EPS estimates for Zentalis Pharmaceuticals in a report issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will earn ($2.33) per share for the year, up from their prior forecast of ($2.83). Wedbush has a "Neutral" rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($3.02) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.48) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($0.88) EPS.
A number of other brokerages also recently weighed in on ZNTL. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday. Oppenheimer reiterated an "outperform" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $10.00.
View Our Latest Stock Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Performance
Shares of NASDAQ ZNTL traded down $0.48 during trading hours on Friday, hitting $3.47. 1,832,087 shares of the stock were exchanged, compared to its average volume of 1,330,826. Zentalis Pharmaceuticals has a 1-year low of $2.66 and a 1-year high of $18.07. The company has a market cap of $247.29 million, a PE ratio of -1.39 and a beta of 1.74. The company's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $5.52.
Institutional Trading of Zentalis Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. ProShare Advisors LLC grew its position in shares of Zentalis Pharmaceuticals by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company's stock valued at $243,000 after buying an additional 1,274 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company's stock valued at $54,999,000 after acquiring an additional 585,644 shares during the last quarter. Kennedy Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the 1st quarter valued at approximately $189,000. Opaleye Management Inc. bought a new position in Zentalis Pharmaceuticals during the 1st quarter worth approximately $3,152,000. Finally, SG Americas Securities LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $58,000.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Articles
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
